Part of its announcement was written like this
Kintara Therapeutics announced financial results for the third quarter of fiscal year 2024 San Diego, May 14, 2024 /PRNewswire/---Kintara Therapeutics, NASDAQ: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on developing new treatments for solid tumor cancers, today announced financial results for the third quarter ended March 31, 2024 and recent company developments. RECENT CORPORATE DEVELOPMENTS • Announced that Kintara has signed a final merger agreement (“Merger Agreement”) with TuHura Biosciences, Inc. (“TuHura”) and Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara, under which Kayak Mergeco will merge with TuHura and join TuHura, Kayak Mergeco, Inc., a wholly-owned subsidiary of TuHura. MergeCo will merge with Tuhura and join Tuhura, TuHura, and survived the merger. It also became a direct wholly-owned subsidiary (“merger”) of Kintara. Under the terms of the merger, TuHura's shareholders will receive Kintara's common shares. Existing shareholders of Kintara will receive contingent value rights (“CVR”), and after registering at least 10 patients in the REM-001 study, they will be entitled to common shares, and each such patient will be followed up for 8 weeks on or before December 31, 2025. According to the terms of the merger agreement, it is estimated that the shareholders of Kintara after the merger will jointly own about 2.85% of the consolidated company's common shares on a fully diluted basis, accounting for about 5.45%, and if the milestone is achieved, including the underlying shares of CVR. The deal is expected to close in the third quarter of 2024. (April 2024) • The inclusion criteria for expanding the REM-001 study of 15 patients with cutaneous metastatic breast cancer (CMBC) were announced to include those receiving pemzumab (KEYTRUDA®) treatment for at least three months at the time of screening. (March 2024) • Announced the launch of an open-label study in patients with CMBC that is evaluating the second-generation photodynamic therapy (PDT) photosensitizer, REM-001, to test a 0.8 mg dose and optimize the study design before the phase 3 trial begins. The study's primary endpoint was the optimal overall objective response rate (BoRR) (complete response or partial response) for the target treatment area at any time from treatment to week 24 (including week 24). Much of the cost of carrying out the study will be covered by Kintara from a $2 million Small Business Innovation Research (SBIR) grant from the US National Institutes of Health (NIH). (February 2024) • Announced that Kintara has received a letter from Nasdaq Stock Markets LLC stating that it has resumed compliance with NASDAQ's minimum shareholder rights requirements. (February 2024) Summary of financial results for the third quarter of fiscal year 2023 ending March 31, 2024 As of March 31, 2024, Kintara's cash and cash equivalents were approximately US$6.35 million.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
luckme OP : They have signed the final merger, but they haven't finished it